A Dose-response Study With Strontium Malonate in Postmenopausal Women. A 12 Week, Multi National, Double Blind, Randomized, 5 Arms, Parallel Group Placebo Controlled Open Label Active Controlled, Phase II Study With 3 Dose Levels of Strontium Malonate and Protelos Within Post Menopausal Women With a BMDT-score Below -1

The primary objective of the study is to compare dose-response effect of three dose levels of strontium malonate to placebo on bone resorption quantified by S-CTX-1 following 12 weeks of treatment.

Start Date01 Dec 2006

Sponsor / Collaborator

Osteologix Holdings Plc

EUCTR2006-003615-40-DK / Not yet recruitingNot Applicable

A dose-response study with stronitum malonate in postmenopausal women. 12 week, multinational, double-blind, randomised, 5 arms, parallel group placebo controlled, open label active controlled, phaseII study with 3 dose levels of strontium malonate and Protelos within post menopausal women with a BMD T-score below -1.

Start Date10 Oct 2006

Sponsor / Collaborator-

100 Clinical Results associated with Strontium Malonate

100 Translational Medicine associated with Strontium Malonate

100 Patents (Medical) associated with Strontium Malonate

519

Literatures (Medical) associated with Strontium Malonate

01 Nov 2024·TOXICON

Exploring nematicidal biomolecules from Xenorhabdus nematophila as a novel source for Meloidogyne incognita management

Article

Author: S G, Shandeep ; T, Deeikshana ; S, Prabhu ; R, Poorniammal ; S, Vijay

Attempts were made to evaluate the purified bioactive compounds of Xenorhabdus nematophila against Meloidogyne incognita. In order to extract the purified compounds, a solid-supported liquid-liquid extraction system with a flow rate (1 mL/min) was used to purify bioactive molecules. Compounds were individually collected concentrated and evaluated against M. incognita. Among 25 fractions the L19 fraction, exhibited 98% inhibition in egg hatching and mortality of juveniles. The biomolecules were identified through Liquid Chromatography- Mass Spectroscopy (LC-MS) technique. To decipher the mode of action of compounds, molecular docking studies were performed with potential protein targets such as acetylcholinesterase, β-1,4-endoglucanase, glutathione S-transferase-1, cytochrome c oxidase, G-protein coupled receptor and Fatty acid and retinol-binding proteins of M. incognita. The results revealed that among eight compounds from the L19 fraction, malonate and pidopidon exhibited greater binding affinity towards the selected protein targets of M. incognita. In vitro studies with malonate and pidopidon against M. incognita showcased a 99% reduction in egg hatching and juvenile mortality. Moreover, greenhouse experiments revealed that malonate compounds not only reduced 94% of the M. incognita population but also enhanced the plant growth parameters in tomato by 60%. Hence the present study stands novel in exploiting the nematicidal compounds from X. nematophila giving limelight to explore pidopidon and malonate as novel nematicidal compounds for the management of M. incognita.

01 Jul 2024·JOURNAL OF INORGANIC BIOCHEMISTRY

Navigating through the coordination preferences of heavy alkaline earth metals: Laying the foundations for 223Ra- and 131/135mBa-based targeted alpha therapy and theranostics of cancer

Article

Author: Madabeni, Andrea ; Orian, Laura ; Di Marco, Valerio ; Asti, Mattia ; Franchi, Sara ; Gentile, Silvia ; Tosato, Marianna

The clinical success of [²²³Ra]RaCl₂ (Xofigo®) for the palliative treatment of bone metastases in patients with prostate cancer has highlighted the therapeutic potential of α-particle emission. Expanding the applicability of radium-223 in Targeted Alpha Therapy of non-osseous tumors is followed up with significant interest, as it holds the potential to unveil novel treatment options in the comprehensive management of cancer. Moreover, the use of barium radionuclides, like barium-131 and -135m, is still unfamiliar in nuclear medicine applications, although they can be considered as radium-223 surrogates for imaging purposes. Enabling these applications requires the establishment of chelators able to form stable complexes with radium and barium radionuclides. Until now, only a limited number of ligands have been suggested and these molecules have been primarily inspired by existing structures known for their ability to complex large metal cations. However, a systematic inspection of chelators specifically tailored to Ra²⁺ and Ba²⁺ has yet to be conducted. This work delves into a comprehensive investigation of a series of small organic ligands, aiming to unveil the coordination preferences of both radium-223 and barium-131/135m. Electronic binding energies of both metal cations to each ligand were theoretically computed via Density Functional Theory calculations (COSMO-ZORA-PBE-D3/TZ2P), while thermodynamic stability constants were experimentally determined for Ba²⁺-ligand complexes by potentiometry, NMR and UV-Vis spectroscopies. The outcomes revealed malonate, 2-hydroxypyridine 1-oxide and picolinate as the most favorable building blocks to design multidentate chelators. These findings serve as foundation guidelines, propelling the development of cutting-edge radium-223- and barium-131/135m-based radiopharmaceuticals for Targeted Alpha Therapy and theranostics of cancer.

01 Jun 2024·Redox Biology

A model of mitochondrial superoxide production during ischaemia-reperfusion injury for therapeutic development and mechanistic understanding

Article

Author: Murphy, Michael P ; Miljkovic, Jan Lj ; Sorby-Adams, Annabel ; Krieg, Thomas ; Prag, Hiran A ; Prime, Tracy A

Ischaemia-reperfusion (IR) injury is the paradoxical consequence of the rapid restoration of blood flow to an ischaemic organ. Although reperfusion is essential for tissue survival in conditions such as myocardial infarction and stroke, the excessive production of mitochondrial reactive oxygen species (ROS) upon reperfusion initiates the oxidative damage that underlies IR injury, by causing cell death and inflammation. This ROS production is caused by an accumulation of the mitochondrial metabolite succinate during ischaemia, followed by its rapid oxidation upon reperfusion by succinate dehydrogenase (SDH), driving superoxide production at complex I by reverse electron transport. Inhibitors of SDH, such as malonate, show therapeutic potential by decreasing succinate oxidation and superoxide production upon reperfusion. To better understand the mechanism of mitochondrial ROS production upon reperfusion and to assess potential therapies, we set up an in vitro model of IR injury. For this, isolated mitochondria were incubated anoxically with succinate to mimic ischaemia and then rapidly reoxygenated to replicate reperfusion, driving a burst of ROS formation. Using this system, we assess the factors that contribute to the magnitude of mitochondrial ROS production in heart, brain, and kidney mitochondria, as well as screening for inhibitors of succinate oxidation with therapeutic potential.

News (Medical) associated with Strontium Malonate

16 Oct 2024

·www.prnewswire.com

OptMed Inc. receives clearance from the U.S. Food & Drug Administration (FDA) for its 510(k) TearRepair™ Liquid Skin Protectant

NEW YORK, Oct. 16, 2024 /PRNewswire/ -- OptMed, Inc. proudly announces it has received a letter from the U.S.Food & Drug Administration (FDA) clearing its 510(k) TearRepair™ Liquid Skin Protectant. TearRepair™ Liquid Skin Protectant is a non-cytotoxic, methylidene malonate based, rapid-drying liquid barrier film for the protection of the skin. It is applied as a liquid and dries within minutes, adhering to the contours of the skin to form a transparent flexible film. TearRepair™ will wear off naturally and is provided sterile. Ervin Braun, OptMed CEO commented, "This is a significant and important milestone for our company. OptMed will aggressively move forward to commercialize TearRepair™. Braun added, "OptMed's proprietary methylidene malonate platform technology provides the company flexibility to further develop new product options to protect skin as well as address acute, surgical, and chronic wounds like lacerations, incisions, open wounds, and potentially internal applications." Optmed, Inc. has been developing a completely new and revolutionary medical adhesive for over 10 years, whose chemistry, methylidene malonate, is unlike any other chemistry offered to the market and indeed may be integral to revolutionizing surgical procedures in the future. OptMed, Inc. is a privately held medical device company that is engaged in the development, manufacturing, and commercialization of methylidene malonate-based products. With this FDA clearance, Optmed now can offer a line of skin protectants and topical surgical adhesives. While this is a significant milestone for the company, Optmed's future steps include pursuing the internal surgical adhesive market with its proprietary polymer chemistry. For more information contact: Ervin Braun CEO - OptMed M:(203) 273-7450 E-Mail: [email protected] SOURCE Optmed, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Strontium Malonate

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05732

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
ST Elevation Myocardial Infarction	Phase 2	US	Caladrius Biosciences, Inc.	01 Dec 2011
Osteoporosis	Phase 2	DK	Osteologix Holdings Plc	01 Dec 2006
Osteoporosis	Phase 2	GB	Osteologix Holdings Plc	01 Dec 2006
Osteoporosis, Postmenopausal	Phase 2	DK	-	26 Nov 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis